<DOC>
	<DOCNO>NCT00840541</DOCNO>
	<brief_summary>The purpose study validate characterize phenotype diabetic retinopathy ( DR ) progression base available clinical data ( demographic , systemic ophthalmic data ) .</brief_summary>
	<brief_title>Phenotyping Diabetic Retinopathy</brief_title>
	<detailed_description>This study aim validate characterize phenotype diabetic retinopathy ( DR ) progression use ophthalmic systemic data type-2 diabetic subject follow AIBILI Clinical Trial Center last 10 year . Macular Edema ( ME ) development study period , mainly Clinically Significant ME ( CSME ) need treatment , primary indicator DR progression . CSME consider primary end-point use identify phenotype ( risk marker ) DR progression .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Diagnosis DR . Females Males ; Age 18 year ; Signed Informed Consent ; Previous followup regular systemic ophthalmic assessment . Cataract eye disease may interfere fundus examination ; Vitreous syneresis posterior vitreous detachment ; Dilatation pupil &lt; 5 mm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>